PAPER So PP, Zeldich E, Seyb KI, Huang MM, Concannon JB, King GD, Chen CD, Cuny GD, Glicksman MA, Abraham CR
SEARCH RESULTS
330988 RESULTS
PAPER Colom-Cadena M, Gelpi E, Martí MJ, Charif S, Dols-Icardo O, Blesa R, Clarimón J, Lleó A
MAPT H1 haplotype is associated with enhanced α-synuclein deposition in dementia with Lewy bodies.
Neurobiol Aging. 2012 Jul 20; PubMed: 22819391PAPER Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, Bertelsen S, Hinrichs A, Alzheimer's Disease Neuroimaging Initiative, Fagan AM, Holtzman DM, Morris JC, Goate AM
Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease.
Hum Mol Genet. 2012 Oct 15;21(20):4558-71. Epub 2012 Jul 20 PubMed: 22821396PAPER Darlington D, Deng J, Giunta B, Hou H, Sanberg CD, Kuzmin-Nichols N, Zhou HD, Mori T, Ehrhart J, Sanberg PR, Tan J
Multiple Low-Dose Infusions of Human Umbilical Cord Blood Cells Improve Cognitive Impairments and Reduce Amyloid-β-Associated Neuropathology in Alzheimer Mice.
Stem Cells Dev. 2012 Sep 5; PubMed: 22816379PAPER Yassine N, Lazaris A, Dorner-Ciossek C, Després O, Meyer L, Maitre M, Mensah-Nyagan AG, Cassel JC, Mathis C
Detecting spatial memory deficits beyond blindness in tg2576 Alzheimer mice.
Neurobiol Aging. 2012 Jul 19; PubMed: 22819136PAPER Noël S, Perez F, Pedersen JT, Alies B, Ladeira S, Sayen S, Guillon E, Gras E, Hureau C
A new water-soluble Cu(II) chelator that retrieves Cu from Cu(amyloid-β) species, stops associated ROS production and prevents Cu(II)-induced Aβ aggregation.
J Inorg Biochem. 2012 Jun 7; PubMed: 22819647PAPER Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.
Nat Neurosci. 2012 Sep;15(9):1227-35. Epub 2012 Jul 22 PubMed: 22820466Lon S. Schneider on No Pony in There: Bapi Fails Mild to Moderate ApoE4 Carriers
COMMENT The topline results of the Phase 3, bapineuzumab trial 302 are disappointing but not surprising. That is mainly because the prior Phase 2, 201 trial was a multiple ascending dose trial, not planned as an efficacy trial, and didn’t show reliable efficacy e
PAPER Pica-Mendez AM, Tanen M, Dallob A, Tanaka W, Laterza OF